Exogenous GLP-1 products that are resistant to DPP4 degradation, same actions as the endogenous incretin.
Also known as incretin mimetics.
Exenatide a 2xd inj. approved 2005 for use with metformin and/or a sulfonylurea. SE: n/v/diar, hypoglyc (esp with sulfas), w. loss. Contra: GI dz, renal Cr <30mL/min. Current trials for once weekly injection.
Liraglutide is awaiting approval. Has longer half life than Byetta thus only requiring once daily injections. Same SE, no contraindications identified yet.
Ahrén B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-treated patients with type 2 diabetes. Diabetes Care 27(12):2874-2880, 2004.
Ahrén B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin in Metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care. 2005;28(8):1936-1940.
ADA. Standards of Medical Care in Diabetes – 2006 . Diabetes Care 2006;29:S4-S42.
ADA. Standards of Medical Care in Diabetes-2007. Diabetes Care 2007:30:S4-41S.
ADA Total prevalence of diabetes and pre-diabetes. www.diabetes.org
Baggio LL, Drucker DJ . American Diabetes Association’s 66th Annual Scientific Sessions-Incretin-Based Therapies- Incretin analogs other than Exenatide. Medscape Diabetes & Endocrinology, Jul 25 2006. URL: http://www.medscape.com/viewarticle/540919, Accessed 11/29/06.
Baggio LL, Drucker DJ. Incretin Hormones in the Treatment of Type 2 Diabetes: Therapeutic Applications of DPP-IV Inhibitors. Medscape Diabetes & Endocrinology. Apr 2006. URL: http://www.medscape.com/viewarticle/530215 , Accessed 11/20/06.
Brophy JM. Selling safety—lessons from muraglitazar. JAMA. 2005;294:2633-2635.
Cara JF. Type 2 diabetes mellitus in children. 2000 American Academy of Pediatrics Annual Meeting . Nov 2000. Medscape conference coverage. URL: http://www.medscape.com/viewarticle/420203 , Accessed 12/2/06.
Craig CR, Stitzel RE. Modern Pharmacology with Clinical Applications. Lippincott Williams and Wilkins, 2004: 763-776.
Conlon D. Goodbye glitazars?. Br J Diabetes Vasc Dis. 2006;6(3):135-137.
Dale DC, Federman DD, Antman K, Atkinson JP, Cassel CK, Feldman M, et al. ACP medicine textbook. WebMD publishing, 2006: 615-649.
FDA approved drug products. www.fda.gov .
Gavin JR, Conner CS, Drucker DJ, Kahn SE. The clinical impact of incretin-based therapies on type 2 diabetes management, one year later. From the American Diabetes Association’s 66th Annual Scientific Sessions. Consensus medical communications. June 9, 2006.
Hansotia T, Drucker DJ. Therapeutic potential of the DPP-IV inhibitors. 65th Scientific Sessions of the American Diabetes Association . Medscape Diabetes & Endocrinology, Jul 2005. URL: http://www.medscape.com/viewarticle/508221, Accessed 11/29/06 .
Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, MD, Fineman MS, et al. Effects of Exenatide on glycemic control over 30 weeks in patients with type 2 diabetes treated with Metformin and a Sulfonylurea. Diabetes Care 2005;28 (5): 1083-1091.
Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (α/γ) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2006;29(5):1016-1023.